John Evans, Beam Therapeutics CEO

September 5, 2023 07:35 AM EDT

Beam doses first patient with base-edited cell therapy

Lei Lei Wu

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

A new dawn for psychedelics? Compass could be the first to find out

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

Weeks after TIGIT fail, iTeos decides to wind down

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation